Informações:
Falhas:
ID
39579
Descrição
Relapse Rate in Hepatitis C Patients Treated With Peginterferon Alfa-2b Plus Ribavirin in Common Clinical Practice in France (P05484)(Completed); ODM derived from: https://clinicaltrials.gov/show/NCT00725842
Link
https://clinicaltrials.gov/show/NCT00725842
Palavras-chave
Versões (1)
- 31/01/2020 31/01/2020 -
Titular dos direitos
See clinicaltrials.gov
Transferido a
31 de janeiro de 2020
DOI
Para um pedido faça login.
Licença
Creative Commons BY 4.0
Comentários do modelo :
Aqui pode comentar o modelo. Pode comentá-lo especificamente através dos balões de texto nos grupos de itens e itens.
Comentários do grupo de itens para :
Comentários do item para :
Para descarregar formulários, precisa de ter uma sessão iniciada. Por favor faça login ou registe-se gratuitamente.
Eligibility Hepatitis C NCT00725842
Eligibility Hepatitis C NCT00725842
- StudyEvent: Eligibility
Similar models
Eligibility Hepatitis C NCT00725842
- StudyEvent: Eligibility
Name
Tipo
Description | Question | Decode (Coded Value)
Tipo de dados
Alias
Study Subject Participation Status Willing
Item
the patient must demonstrate his/her continued willingness to participate in the study.
boolean
C2348568 (UMLS CUI [1,1])
C0600109 (UMLS CUI [1,2])
C0600109 (UMLS CUI [1,2])
Age
Item
the patient must be at least 18 years of age, of either gender.
boolean
C0001779 (UMLS CUI [1])
Chronic Hepatitis C Genotype Any | peginterferon alfa-2b
Item
patients with chronic hepatitis c (any genotype) who received peg-ifn alfa-2b +
boolean
C0524910 (UMLS CUI [1,1])
C1148363 (UMLS CUI [1,2])
C1552551 (UMLS CUI [1,3])
C0796545 (UMLS CUI [2])
C1148363 (UMLS CUI [1,2])
C1552551 (UMLS CUI [1,3])
C0796545 (UMLS CUI [2])
Ribavirin | Primary treatment Hepatitis C
Item
ribavirin as first treatment for hepatitis c.
boolean
C0035525 (UMLS CUI [1])
C1708063 (UMLS CUI [2,1])
C0019196 (UMLS CUI [2,2])
C1708063 (UMLS CUI [2,1])
C0019196 (UMLS CUI [2,2])
Hepatitis C RNA negative Assay
Item
negative hcv-rna at the end of treatment (24 or 48 weeks according to the product labeling as appropriate), measured by the assay used at each institution. only institutions using an assay with a limit of detection of 50 iu/ml or less will be eligible.
boolean
C0855841 (UMLS CUI [1,1])
C1510438 (UMLS CUI [1,2])
C1510438 (UMLS CUI [1,2])
Treatment completed | Peginterferon alfa-2b Plus Ribavirin
Item
patients who completed treatment with peginterferon alfa-2b plus ribavirin more than 4 weeks before study entry.
boolean
C0580352 (UMLS CUI [1])
C0796545 (UMLS CUI [2,1])
C0332287 (UMLS CUI [2,2])
C0035525 (UMLS CUI [2,3])
C0796545 (UMLS CUI [2,1])
C0332287 (UMLS CUI [2,2])
C0035525 (UMLS CUI [2,3])
Hepatitis C RNA positive | Treatment completed
Item
patients with positive hcv-rna at the end of treatment (24 or 48 weeks according to the product labeling as appropriate).
boolean
C0855842 (UMLS CUI [1])
C0580352 (UMLS CUI [2])
C0580352 (UMLS CUI [2])
Treatment Time period Inadequate
Item
patients treated for a period shorter than the enrollment period.
boolean
C0087111 (UMLS CUI [1,1])
C1948053 (UMLS CUI [1,2])
C0205412 (UMLS CUI [1,3])
C1948053 (UMLS CUI [1,2])
C0205412 (UMLS CUI [1,3])
Human immunodeficiency virus (HIV) coinfection
Item
patients co-infected with human immunodeficiency virus (hiv).
boolean
C4062778 (UMLS CUI [1])
HBV coinfection
Item
patients co-infected with hepatitis b virus (hbv).
boolean
C2242656 (UMLS CUI [1])
Contraceptive methods Inappropriate | Status post Treatment
Item
patients who do not use appropriate effective method of birth control after the end of treatment (according to legal recommendations).
boolean
C0700589 (UMLS CUI [1,1])
C1548788 (UMLS CUI [1,2])
C0231290 (UMLS CUI [2,1])
C0087111 (UMLS CUI [2,2])
C1548788 (UMLS CUI [1,2])
C0231290 (UMLS CUI [2,1])
C0087111 (UMLS CUI [2,2])